Literature DB >> 7544393

Identification of residues in the V domain of CD80 (B7-1) implicated in functional interactions with CD28 and CTLA4.

C A Fargeas1, A Truneh, M Reddy, M Hurle, R Sweet, R P Sékaly.   

Abstract

The CD80 (B7-1) molecule is a 45-60-kD member of the immunoglobulin superfamily that is expressed on a variety of cell types of haematopoietic origin. CD80 can provide a critical costimulatory signal to T cells by interacting with the T cell surface molecule CD28. CD80 also binds to the CD28-related molecule CTLA4, which is expressed on activated T cells, Recently, additional ligands of CD28 and CTLA4 have been described in mice and humans. One of them, CD86 (B-70 or B7-2) was characterized at the molecular level. Although similar in predicted structure to CD80, it is distantly related in amino acid sequence. In this study, human CD80 mutants were generated and tested for their ability to maintain the interaction with CD28 leading to adhesion and enhanced IL-2 production. Two hydrophobic residues in the V-like domain of CD80 were identified as critical for binding to CD28 and are also important for the interaction with CTLA4. These residues are adjacent to the epitope of the BB1 antibody, which inhibits CD28-CD80 interactions. One of these residues, Y87, is conserved in all CD80 and CD86 cloned from various species. These results being to unravel the structural requirements for binding to CD28 and CTLA4.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7544393      PMCID: PMC2192168          DOI: 10.1084/jem.182.3.667

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  34 in total

1.  Crystal structure of an HIV-binding recombinant fragment of human CD4.

Authors:  S E Ryu; P D Kwong; A Truneh; T G Porter; J Arthos; M Rosenberg; X P Dai; N H Xuong; R Axel; R W Sweet
Journal:  Nature       Date:  1990-11-29       Impact factor: 49.962

2.  Structure of domain 1 of rat T lymphocyte CD2 antigen.

Authors:  P C Driscoll; J G Cyster; I D Campbell; A F Williams
Journal:  Nature       Date:  1991-10-24       Impact factor: 49.962

3.  CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells.

Authors:  M K Jenkins; P S Taylor; S D Norton; K B Urdahl
Journal:  J Immunol       Date:  1991-10-15       Impact factor: 5.422

4.  CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location.

Authors:  K Harper; C Balzano; E Rouvier; M G Mattéi; M F Luciani; P Golstein
Journal:  J Immunol       Date:  1991-08-01       Impact factor: 5.422

5.  mAb 104, a new monoclonal antibody, recognizes the B7 antigen that is expressed on activated B cells and HTLV-1-transformed T cells.

Authors:  A Vallé; P Garrone; H Yssel; J Y Bonnefoy; A S Freedman; G Freeman; L M Nadler; J Banchereau
Journal:  Immunology       Date:  1990-04       Impact factor: 7.397

6.  Involvement of CD28 in MHC-unrestricted cytotoxicity mediated by a human natural killer leukemia cell line.

Authors:  M Azuma; M Cayabyab; D Buck; J H Phillips; L L Lanier
Journal:  J Immunol       Date:  1992-08-15       Impact factor: 5.422

7.  Expression and function of the murine B7 antigen, the major costimulatory molecule expressed by peritoneal exudate cells.

Authors:  Z Razi-Wolf; G J Freeman; F Galvin; B Benacerraf; L Nadler; H Reiser
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

8.  CD28-stimulated IL-2 gene expression in Jurkat T cells occurs in part transcriptionally and is cyclosporine-A sensitive.

Authors:  T M Williams; D M Moolten; H Makni; H W Kim; J A Kant; M Kamoun
Journal:  J Immunol       Date:  1992-04-15       Impact factor: 5.422

9.  Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7.

Authors:  G J Freeman; G S Gray; C D Gimmi; D B Lombard; L J Zhou; M White; J D Fingeroth; J G Gribben; L M Nadler
Journal:  J Exp Med       Date:  1991-09-01       Impact factor: 14.307

10.  CTLA-4 is a second receptor for the B cell activation antigen B7.

Authors:  P S Linsley; W Brady; M Urnes; L S Grosmaire; N K Damle; J A Ledbetter
Journal:  J Exp Med       Date:  1991-09-01       Impact factor: 14.307

View more
  7 in total

Review 1.  CD28/CTLA-4 and CD80/CD86 families: signaling and function.

Authors:  J M Slavik; J E Hutchcroft; B E Bierer
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

2.  Effects of superantigen and lipopolysaccharide on induction of CD80 through apoptosis of human monocytes.

Authors:  M Takahashi; M Takahashi; F Shinohara; H Takada; H Rikiishi
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

Review 3.  CD28: a signalling perspective.

Authors:  S G Ward
Journal:  Biochem J       Date:  1996-09-01       Impact factor: 3.857

Review 4.  Role of the CTLA-4 receptor in T cell activation and immunity. Physiologic function of the CTLA-4 receptor.

Authors:  P Scheipers; H Reiser
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

5.  CTLA-4-B7 interaction is sufficient to costimulate T cell clonal expansion.

Authors:  Y Wu; Y Guo; A Huang; P Zheng; Y Liu
Journal:  J Exp Med       Date:  1997-04-07       Impact factor: 14.307

6.  B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells.

Authors:  S Y Tseng; M Otsuji; K Gorski; X Huang; J E Slansky; S I Pai; A Shalabi; T Shin; D M Pardoll; H Tsuchiya
Journal:  J Exp Med       Date:  2001-04-02       Impact factor: 14.307

7.  The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity.

Authors:  Mark F Maurer; Katherine E Lewis; Joseph L Kuijper; Dan Ardourel; Chelsea J Gudgeon; Siddarth Chandrasekaran; Sherri L Mudri; Kayla N Kleist; Chris Navas; Martin F Wolfson; Mark W Rixon; Ryan Swanson; Stacey R Dillon; Steven D Levin; Yengo Raymond Kimbung; Masato Akutsu; Derek T Logan; Björn Walse; Kristine M Swiderek; Stanford L Peng
Journal:  Nat Commun       Date:  2022-04-04       Impact factor: 17.694

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.